




RealRate

PHARMACEUTICAL 2020

ALNYLAM PHARMACEUTICALS INC.
Rank 149 of 362

Alnylam@20



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of ALNYLAM PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALNYLAM PHARMACEUTICALS INC. compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 38% points. The greatest weakness of ALNYLAM PHARMACEUTICALS INC. is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is -121%, being 182% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	1,715,864
Cost of Goods Sold	25,062
Intangible Assets	0
Liabilities, Current	352,594
Liabilities, Non-Current	603,848
Other Assets	254,091
Other Compr. Net Income	-3,305
Other Expenses	863
Other Liabilities	0
Other Net Income	54,178
Property and Equipment	425,179
Research and Development	655,114
Revenues	219,750
Selling, General and Administrative Expense	479,005

Output Variable	Value in 1000 USD
Assets	2,395,134
Liabilities	956,442
Expenses	1,160,044
Stockholders Equity	1,438,692
Net Income	-886,116
Comprehensive Net Income	-887,768
Economic Capital Ratio	-121%